# US 2010/0247536 A1 · Oncofetal antigen/immature laminin receptor antibodies for diagnostic and clinical applications

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0247536 A1
- Document ID: US20100247536A1
- Status: Published application
- Kind: A1
- Application number: 12/732,880
- Filed: 2010-03-26
- Published: 2010-09-30
- Earliest claimed: 2009-03-26
- Assignees: Quantum Immunologics, Inc.
- Inventors: Eric W. Olle
- Web page: https://patentgrep.com/patent/US20100247536A1

## CPC

- C07K 16/30: from tumour cells
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6905: {the form being a colloid or an emulsion}
- A61K 49/04: X-ray contrast preparations
- A61K 51/1045: {against animal or human tumor cells or tumor cell determinants}
- A61K 51/1093: {conjugates with carriers being antibodies}
- A61P 35/00: Antineoplastic agents
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/3076: {against structure-related tumour-associated moieties}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to antibodies against Oncofetal Antigen/immature Laminin receptor protein (OFA/iLRP) that can be used singly or in conjunction to detect or treat OFA/iLRP-related diseases. More specifically, the antibodies can be used for several purposes including: (i) detecting and measuring OFA/iLRP in different biofluids; and (ii) using OFA/iLRP with an antibody directed against the monomeric form and its associated diseases.

## Claims

### Claim 1

An isolated antibody that specifically binds to a region of the oncofetal antigen/immature laminin receptor protein (OFA/iLRP), wherein the region is immunogenic.

### Claim 2 (depends on 1)

The isolated antibody of claim 1, wherein the immunogenic region is located in the dimerization region of OFA/iLRP.

### Claim 3 (depends on 1)

The isolated antibody of claim 1, wherein the region of OFA/iLRP comprises a polypeptide sequence of (a) FFREPRLLVVTDPR, (b) VTDPRADHQPLTE, (c) YRDPEEIEKEEQ, or (d) FPTEDWSAQPATED.

### Claim 4 (depends on 1)

The isolated antibody of claim 1, wherein the region OFA/iLRP is conjugated to a peptide that increases an immunogenic response.

### Claim 5 (depends on 1)

The isolated antibody of claim 1, wherein OFA/iLRP is conjugated to Keyhole Limpet hemocyanin, ovalbumin, or serum albumin.

### Claim 6 (depends on 1)

The isolated antibody of claim 1, wherein the antibody is a monoclonal antibody.

### Claim 7 (depends on 6)

The isolated antibody of claim 6, wherein the monoclonal antibody is 2C6 or 3G7.

### Claim 8 (depends on 6)

The isolated antibody of claim 6, wherein the region comprises the polypeptide sequence of FREPRLLVVTDPRC or YRDPEEIEKEEQC.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising the antibody of claim 1.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the antibody is a monoclonal antibody.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the monoclonal antibody is 3G7 or 2C6.

### Claim 12 (depends on 9)

The composition of claim 9, further comprising a pharmaceutically acceptable carrier.

### Claim 13

A method of detecting OFA/iLRP in a sample comprising:
(a) contacting the sample with a first and a second antibody that specifically bind to a region of OFA/iLRP, wherein at least one of the antibodies is specific for OFA/iLRP;
(b) allowing the antibodies to bind to OFA/iLRP and form a sandwich with OFA/iLRP; and
(c) detecting the expression of OFA/iLR in the sample using the antibody specific for OFA/iLRP.

### Claim 14 (depends on 13)

A method in accordance with claim 13, wherein one of the antibodies binds to both OFA/iLRP and mature LRP.

### Claim 15 (depends on 14)

A method of claim 14, wherein the antibody recognize both OFA/iLRP and mature LRP acts as a capture antibody, and the antibody specific for OFA/iLRP acts as a detection antibody.

### Claim 16 (depends on 13)

A method of claim 13, wherein the first antibody is 3G7, and the second antibody is 2C6.

### Claim 17

A method of detecting cancer in a sample comprising:
(a) contacting the sample with antibodies specific for OFA/iLRP;
(b) contacting the sample with a biotinylated secondary antibody; and
(c) detecting OFA/iLRP in the sample using streptavidin,
wherein the detection of OFA/iLRP in the sample is indicative of cancer.

### Claim 18

A method of determining the amount of OFA/iLRP in a sample comprising:
(a) conjugating an antibody specific for OFA/iLRP to a fluorophore;
(b) contacting the conjugated antibody with sample; and
(c) determining the amount of OFA/iLRP in the sample using fluorescent polarization.

### Claim 19

A method of determining the amount of OFA/iLRP positive cancer cells in a blood sample comprising:
(a) contacting a blood sample with an antibody specific for OFA/iLRP and
(b) determining the amount of OFA/iLRP in the sample using flow cytometry.

### Claim 20

A method of treating a OFA/iLRP positive cancer comprising administering an amount of antibodies specific for OFA/iLRP to a subject with the OFA/iLRP positive cancer that are in an amount sufficient to treat the cancer.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the antibodies are linked to colloids having anti-cancer properties.

### Claim 22 (depends on 19)

The method according to claim 19, wherein the antibodies are conjugated with chemotherapeutic agents.

### Claim 23 (depends on 19)

The method according to claim 19, wherein the antibodies are conjugated with proteins.

### Claim 24

A method of detecting a OFA/iLRP positive cancer in a subject comprising:
(a) conjugating antibodies specific for OFA/iLRP to a radio opaque dye;
(b) administering the conjugated antibody to a subject; and
(c) detecting the conjugated antibody using an x-ray,
wherein the detection of OFA/iLRP on the x-ray is indicative of cancer.
